Description
PEGylation of biologics prolongs their half-life by slowing proteolytic degradation and decreasing the rate of clearance from the circulatory system. The pharmacodynamics of PEGylated proteins are often evaluated using specific assays for the protein itself. That approach often requires the time consuming and expensive construction of an ELISA for the protein of interest. The PEG ELISA allows measurement of the PEG portion of the PEGylated protein and is therefore suitable for assessment of the pharmacodynamics of a range of PEGylated proteins